Current and future strategies in the treatment of hypertension

Standardized health plan reporting in four areas of preventive health care

PURPOSE

This paper discusses first-year reporting by commercial managed care organizations (MCOs) of new measures in the 2000 Health Plan Employer Data and Information Set (HEDIS). The four measures include screening for chlamydia in young women, controlling blood pressure to <140/90mmHg in patients with hypertension, prescribing appropriate medications for persons with asthma (treatment adherence), and providing counseling to women about managing menopause (survey measure).

METHODS

In 2000, some 384 commercial MCOs submitted HEDIS results to the National Committee for Quality Assurance (NCQA). Results of the four new HEDIS measures were linked with audit reports and other health plan data-reporting characteristics collected by NCQA. Performance variables were stratified by MCOs' willingness to report their results publicly, size of enrollment, performance on other (non-first year) HEDIS measures, and data collection issues.

RESULTS

The mean average performance on the four measures was lowest in chlamydia screening in women (16% for ages 21 to 26 years) and highest for use of appropriate medications for people with asthma (59% for ages 18 to 56 years). The mean average of controlling high blood pressure was 39%. Scores on the management of menopause (MoM) measure ranged from 33.7 (for rating of information) to 72.6 (for exposure to counseling).

CONCLUSIONS

The initial MCO baseline rates reported here suggest that much work is needed to improve the quality of care in these areas. Plan characteristics shown to be associated with higher performance on existing HEDIS measures do not predict performance on the new measures. In addition, fewer plans reported on the new measures than on established HEDIS measures. To ensure continued improvement in chlamydia screening in women, controlling high blood pressure, use of appropriate medications for people with asthma, and MoM, incentives for tracking and reporting on these health issues must be explored.

The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide

OBJECTIVES

To assess the peripheral and central haemodynamics, in particular the effect on minimal resistance in the hand, with an ACE inhibitor in comparison with a diuretic.

DESIGN

Double-blind randomized parallel group study.

SUBJECTS

Twenty-eight previously untreated men with essential hypertension (supine diastolic blood pressure > 95 mmHg repeatedly on placebo). METHODS/INTERVENTION: Causal and intra-arterial blood pressure, dye-dilution technique, water plethysmography at rest and at ischaemia, enalapril (n = 14), hydrochlorothiazide (n = 14).

RESULTS

After 6 months the mean arterial pressure was reduced from 112.7 to 96.9 mmHg (change -15.9 mmHg; 95% confidence interval (CI) -21.9, -9.8) on enalapril and from 110.1 to 101.5 mmHg (change -8.6 mmHg; CI -14.4, -2.8). Heart rate did not change on any of the therapies. Enalapril reduced blood pressure mainly through a reduction in total peripheral resistance (delta -3.0 PRU100; CI -5.6, -0.4) while hydrochlorothiazide reduced blood pressure mainly through a reduction in cardiac output (delta -0.8 l/min-1; CI -1.5, -0.07). Minimal vascular resistance (mean of right and left hand) displayed a significant time x treatment interaction indicating a different trend with enalapril than hydrochlorothiazide with a change of -0.12 PRU100 (CI -0.33, 0.05) on enalapril and a change of 0.14 (CI -0.29, 0.56) on hydrochlorothiazide. The resistance level after 6 months was significantly higher on hydrochlorothiazide than on enalapril (P = 0.0105).

CONCLUSION

Enalapril reduced blood pressure through vasodilatation and hydrochlorothiazide through decreased cardiac output. The two therapies also affected minimal vascular resistance (an indirect measure of vascular wall thickness) differently; with enalapril showing a favourable response in contrast to hydrochlorothiazide.